2-Mercaptoethanesulfonic Acid: Side Effects, Uses & Monitoring
Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
- Data source
- FDA labeling via NIH DailyMed (label ef161ede…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia.
Conditions associated with 2-Mercaptoethanesulfonic Acid in labeling
Frequently Asked Questions
What is 2-Mercaptoethanesulfonic Acid used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of 2-Mercaptoethanesulfonic Acid?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does 2-Mercaptoethanesulfonic Acid require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking 2-Mercaptoethanesulfonic Acid.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.